The Galderisi group has published several studies demonstrating senescence in RTT patient mesenchymal stem cells (MSCs), partially MECP2-silenced human MSCs, MECP2-silenced human neuroblastoma cells, and heterozygous MECP2 mutant mouse mesenchymal stromal cells and neural stem cells (Alessio et al., 2018; Squillaro et al., 2008, 2010, 2019). The gene discussed is MECP2; the disease is neuroblastoma.